位置:首页 > 产品库 > Heparin Lithium salt
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Heparin Lithium salt
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Heparin Lithium salt图片
CAS NO:9045-22-1

Heparin Lithium salt 是一种抗凝剂,可与 抗凝血酶III (ATIII) 可逆地结合 (50-400 U/Kg)。
Cas No.9045-22-1
别名肝素锂
Canonical SMILESO[C@H]1[C@H](O[C@H]2[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O2)[C@@H](COS(O)(=O)=O)O[C@H](OC)[C@@H]1NS(O)(=O)=O.[n].[.xLi]
分子式(C14H25NO20S3)n.xLi
溶解度Water: 125 mg/mL
储存条件4°C, protect from light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Heparin Lithium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) (50-400 U/Kg). Antithrombin III[1]

Heparin is a potent anticoagulant drug based on its ability to accelerate the rate at which antithrombin inhibits serine proteases in the blood coagulation cascade. Heparin interactes most tightly with peptides containing a complementary binding site of high positive charge density. Heparin resembles DNA as both are highly charged linear polymers that behave as polyelectrolytes. Heparin is believed to function as an anticoagulant primarily through its interaction with AT III by enhancing AT-III-mediated inhibition of blood coagulation factors, including thrombin and factor Xa. Heparin binds to AT III and thrombin in a ternary complex, increasing the bimolecular rate constant for the inhibition of thrombin by a factor of 2000. Heparin is principally located in the granules of tissue mast cells that are closely associated with the immune response. Heparin makes numerous contacts with both FGF-2 and FGFR-1 stabilizing FGF-FGFR binding. Heparin also makes contacts with the FGFR-1 of the adjacent FGF-FGFR complex, thus seeming to promote FGFR dimerization[1].

[1]. Capila I, et al. Heparin-protein interactions. Angew Chem Int Ed Engl. 2002 Feb 1;41(3):391-412.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024